Xencor (XNCR) EPS (Weighted Average and Diluted) (2013 - 2026)
Xencor (XNCR) reported EPS (Weighted Average and Diluted) of -$1.71 for Q1 2026, down 159.09% year-over-year from $2.89 in Q1 2025, and down 1800.0% quarter-over-quarter from -$0.09 in Q4 2025.
Xencor (XNCR) EPS (Weighted Average and Diluted) (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.71 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.71, down 159.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.29 (up 24.92% YoY), and the FY2025 annual result was -$1.24, up 65.36% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$1.71 in Q1 2026 per XNCR's latest filing, from -$0.09 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.39 in Q1 2022 and troughed at -$1.71 in Q1 2026.
- A 5-year average of -$0.57 and a median of -$0.55 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) jumped 1075.0% in 2022, then plunged 361.54% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.21 in 2022, then plunged by 104.76% to -$0.43 in 2023, then slumped by 34.88% to -$0.58 in 2024, then jumped by 84.48% to -$0.09 in 2025, then tumbled by 1800.0% to -$1.71 in 2026.
- Business Quant data shows XNCR's EPS (Weighted Average and Diluted) at -$1.71 in Q1 2026, -$0.09 in Q4 2025, and -$0.08 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -1.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.71 |
| Dec 31, 2025 | -0.09 |
| Sep 30, 2025 | -0.08 |
| Jun 30, 2025 | -0.41 |
| Mar 31, 2025 | -0.66 |
| Dec 31, 2024 | -0.58 |
| Sep 30, 2024 | -0.72 |
| Jun 30, 2024 | -1.09 |
| Mar 31, 2024 | -1.20 |
| Dec 31, 2023 | -0.43 |
| Sep 30, 2023 | -0.40 |
| Jun 30, 2023 | -0.37 |
| Mar 31, 2023 | -1.02 |
| Dec 31, 2022 | -0.21 |
| Sep 30, 2022 | -0.55 |
| Jun 30, 2022 | -0.57 |
| Mar 31, 2022 | 0.39 |
| Dec 31, 2021 | 1.21 |
| Sep 30, 2021 | -0.69 |
| Jun 30, 2021 | 0.87 |